Sponsor

Institut Curie

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Institut Curie appears in 63 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials63
Recruiting shown12
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
Validation of Capillary Microsampling for Therapeutic Drug Monitoring of CDK4/6 Inhibitors in Breast Cancer Patients (TDHOME)NCT07491380 · lead sponsor · 2026-06-23
RECRUITING
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast CancerNCT07193394 · lead sponsor · 2026-01-31
RECRUITING
Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)NCT06225505 · lead sponsor · 2026-01-05
RECRUITING
Screening and Care for Fear of Cancer Recurrence in Patients With Cancer at Institut CurieNCT07357311 · lead sponsor · 2025-09-08
RECRUITING
Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid (AVATAR)NCT06459791 · lead sponsor · 2024-12-06
RECRUITING
68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT)NCT06349512 · lead sponsor · 2024-10-14
RECRUITING
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer PatientsNCT06195709 · lead sponsor · 2024-05-27
RECRUITING
Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast CancerNCT05955170 · lead sponsor · 2023-12-19
RECRUITING
Opioid Free Versus Opioid Based Anaesthesia for Free Flap Reconstruction Surgery of the Breast: A Phase III Multicentric Randomized Controlled Study.NCT05439005 · lead sponsor · 2022-12-07
RECRUITING
LIquid Biopsy to prEdict Responses To First-line immunotherapY in Metastatic Non-small Cell LUNG Cancer. LIBERTY LUNGNCT04790682 · lead sponsor · 2021-05-22
RECRUITING
Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)NCT03017573 · lead sponsor · 2017-01-06
RECRUITING
COsegregation of VARiants in Panel of GenesNCT01689584 · lead sponsor · 2012-07-02
RECRUITING
Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapyNCT07357948 · lead sponsor · 2026-08-01
NOT_YET_RECRUITING
A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid TumorsNCT06337630 · lead sponsor · 2025-01-20
TERMINATED
A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Triple-negative Breast CancerNCT06162351 · lead sponsor · 2024-04-17
TERMINATED
"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast CancerNCT06067061 · lead sponsor · 2024-04-05
TERMINATED
Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast CancerNCT06175390 · lead sponsor · 2024-03-27
ACTIVE_NOT_RECRUITING
Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast CancerNCT05932667 · lead sponsor · 2023-10-12
TERMINATED
Digital Phenotyping in Women Over 70 Years of Age Treated for Breast Cancer With Any Type of TreatmentNCT05634395 · lead sponsor · 2023-02-17
COMPLETED
Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic SignaturesNCT05475366 · lead sponsor · 2022-12-12
ACTIVE_NOT_RECRUITING
Comparative Study of Diagnostic and Prognosis Biomarkers of Prostate Cancer in Liquid Biopsy (HOPE)NCT05141383 · lead sponsor · 2022-05-04
COMPLETED
Real Life Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNGNCT04934865 · lead sponsor · 2021-10-07
COMPLETED
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.NCT04823377 · lead sponsor · 2021-09-24
ACTIVE_NOT_RECRUITING
Digital Phenotyping in Young Breast Cancer Patients Treated With Neoadjuvant ChemotherapyNCT05011721 · lead sponsor · 2021-09-20
COMPLETED
ER-One: A Double-blind Trial of Erector Spinae Block (ESP) Versus Paravertebral Block (PVB) Before Breast Cancer SurgeryNCT04827030 · lead sponsor · 2021-06-28
COMPLETED
Chemotherapy Monitoring by ctDNA in HER2- Metastatic Breast CancerNCT04720729 · lead sponsor · 2021-04-21
TERMINATED
Study Evaluating Hot Flashes in Hormone Sensitive Breast CancerNCT04775043 · lead sponsor · 2021-03-23
COMPLETED
Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)NCT04118062 · lead sponsor · 2021-02-02
COMPLETED
Isolation of Volatile Organic Compounds (VOCs) Related to the Olfactory Signature of Breast Cancer. (KDOGCOV)NCT04541537 · lead sponsor · 2021-01-25
COMPLETED
Study on Skin Toxicities Induced by Cancer TreatmentsNCT04402606 · lead sponsor · 2020-11-25
COMPLETED
Study to Assess the Impact of Personalized Coaching on the Time Period and Quality of Return to Work After Breast CancerNCT04469205 · lead sponsor · 2020-10-05
TERMINATED
MIRs 04 : Interpectoral Nerve Block With Ropivacaine Versus Placebo Before Breast Cancer SurgeryNCT04327063 · lead sponsor · 2020-08-04
COMPLETED
Transcutaneous Breast Cancer Diagnosis by Canine OdorologyNCT04217109 · lead sponsor · 2020-02-03
COMPLETED
Breast Cancer Risk After Diagnostic Gene SequencingNCT04145817 · lead sponsor · 2019-10-22
COMPLETED
Isolation of Volatile Organic Compounds (VOCs) Related to the Olfactory Signature of Breast CancerNCT03703557 · lead sponsor · 2018-07-25
COMPLETED
FErtility, PrEgnancy, contRaceptIon After Breast Cancer in FranceNCT03884413 · lead sponsor · 2018-03-08
COMPLETED
Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)NCT03109080 · lead sponsor · 2017-07-24
COMPLETED
A Feasibility Study to Identify T-cell Responses to Neo-epitopes in Tumor Invaded Lymph Nodes (NeoEpitope)NCT02831634 · lead sponsor · 2016-06-09
COMPLETED
Assessment of Response to Neo-adjuvant Chemotherapy for Patients With a Locally Advanced Breast Cancer With 3D Elastography (Shear Wave), NEOELASTONCT02834494 · lead sponsor · 2016-02-22
COMPLETED
MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer SurgeryNCT02408393 · lead sponsor · 2015-03-27
COMPLETED
Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast CancerNCT02250118 · lead sponsor · 2014-12-09
TERMINATED
Optimizing the Care Pathways of Patients Treated for Operable Breast.NCT02813317 · lead sponsor · 2014-12-01
COMPLETED
Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.NCT01975142 · lead sponsor · 2013-11-07
COMPLETED
Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast CancersNCT01710605 · lead sponsor · 2012-02-01
UNKNOWN
Intrathecal Trastuzumab Administration in Metastatic Breast Cancer Patients Developing Carcinomatous MeningitisNCT01373710 · lead sponsor · 2011-05-19
COMPLETED
Circulating Tumor Cells to Guide Chemotherapy for Metastatic Breast CancerNCT01349842 · lead sponsor · 2010-03-02
COMPLETED
Hydrosorb® Versus Control in the Management of Radio-induced Skin Toxicity: Multicentre Controlled Phase III Randomized TrialNCT02839473 · lead sponsor · 2010-03-01
COMPLETED
Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting (ESOPE)NCT01956552 · lead sponsor · 2009-11-01
TERMINATED
Test Semiquantitative Prostate Specific Antigen (PSA)NCT00853710 · lead sponsor · 2009-03-01
COMPLETED
Study of Tumor and Blood Samples From Women With Breast CancerNCT00897728 · lead sponsor · 2008-02-01
UNKNOWN
Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast CancerNCT00875355 · lead sponsor · 2007-11-01
UNKNOWN
Blood Levels of Tumor Cells in Predicting Response in Patients Receiving First-Line Chemotherapy for Stage IV Breast CancerNCT00898014 · lead sponsor · 2007-05-01
COMPLETED
Chlorhydrate of Ropivacaine and Breast Cancer SurgeryNCT00370240 · lead sponsor · 2006-09-01
COMPLETED
Modelization of Early Endometrial-trophoblast Molecular InteractionNCT07825649 · collaborator · 2026-10-01
NOT_YET_RECRUITING
Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated HypertensionNCT06515678 · collaborator · 2024-05-20
UNKNOWN
Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CTNCT05931302 · collaborator · 2023-11-16
ACTIVE_NOT_RECRUITING
Atrial Fibrillation and Other Cardiac Arrhythmias and Diseases After Radiotherapy for Breast Cancer : Watch Your HeaRTNCT06073509 · collaborator · 2023-10-25
UNKNOWN
De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 BlockadeNCT04675827 · collaborator · 2022-01-17
TERMINATED
Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:NCT03875573 · collaborator · 2019-11-06
ACTIVE_NOT_RECRUITING
Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes.NCT03246841 · collaborator · 2017-09-21
ACTIVE_NOT_RECRUITING

Drugs studied in this sponsor's trials

8 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Institut Curie as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
ropivacaine2
ado-trastuzumab emtansine1
bevacizumab1
dexmedetomidine1
durvalumab1
olaparib1
temozolomide1
trastuzumab1
ropivacaine RxCUI 35780 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials ado-trastuzumab emtansine RxCUI 1371041 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial bevacizumab RxCUI 253337 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial dexmedetomidine RxCUI 48937 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial durvalumab RxCUI 1919503 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial olaparib RxCUI 1597582 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial temozolomide RxCUI 37776 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial trastuzumab RxCUI 224905 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor53
collaborator10
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.